- active not recruitingNA
Biological Characterisation of High Risk CHildhood Cancer in Children, Adolescents and Young Adults (MICCHADO)
This study looks at DNA and immune system features in childhood, teenage, and young adult cancers like neuroblastoma and leukaemia. We aim to better understand these high-risk cancers from diagnosis through treatment to find new ways to help. Participants give blood, bone marrow, or spinal fluid samples.
France - active not recruitingPHASE2
Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors
This study looks at a new drug, palbociclib, combined with standard chemotherapy for children, teenagers, and young adults with certain cancers that have come back or are hard to treat. It aims to find a safe dose and see how well it works.
United States · Brazil · Canada - active not recruitingPHASE3
Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma
This study looks at new ways to treat a type of cancer called rhabdomyosarcoma. It compares standard chemotherapy with chemotherapy plus a drug called temsirolimus, for patients whose cancer has an average chance of coming back. Researchers want to see if adding temsirolimus helps more.
United States · Australia · Canada - recruitingPHASE1, PHASE2
FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma
This study, FaR-RMS, is for children and adults with a type of cancer called rhabdomyosarcoma. It's looking for better ways to treat both newly diagnosed and returning cancer, using different combinations of medicines and radiotherapy.
Australia · Austria · Belgium - ongoing, recruitingPhase I and Phase II (Integrated)- Other
Phase I/II multicenter study to assess efficacy and safety of ribociclib (LEE011) in combination with topotecan and temozolomide (TOTEM) in pediatric patients with relapsed or refractory neuroblastoma and other solid tumors
This study is looking at a new combination of medicines for children and young people with certain types of cancer that have come back or not responded to previous treatments. It aims to find the right dose and see how well the medicines work and if they are safe.
Spain · Germany · France